TABLE 7.
Heterogeneity test between innovative and generic drug companies.
| Innovative drug | Generic drug | |||||
|---|---|---|---|---|---|---|
| Innovation input | Innovation input | Innovation input | Innovation output | |||
| Quantity | Quality | Quantity | Quality | |||
| (1) | (2) | (3) | (4) | (5) | (6) | |
| Pro | 4.325*** | 0.122 | 0.0213 | 0.895*** | −0.290*** | 0.0967*** |
| (1.435) | (0.134) | (0.0231) | (0.303) | (0.0976) | (0.0285) | |
| Constant | 2.809 | 5.487*** | 0.530*** | 1.818 | 0.361 | 0.313*** |
| (10.40) | (1.507) | (0.0993) | (1.799) | (0.452) | (0.0555) | |
| Control variables | Yes | Yes | Yes | Yes | Yes | Yes |
| Company dummies | Yes | Yes | Yes | Yes | Yes | Yes |
| Year dummies | Yes | Yes | Yes | Yes | Yes | Yes |
| Observations | 184 | 184 | 184 | 1128 | 1128 | 1128 |
| R-squared | 0.376 | 0.161 | 0.115 | 0.193 | 0.038 | 0.020 |
| Number of Company | 23 | 23 | 23 | 141 | 141 | 141 |
Note: Robust standard errors clustered at the company level in parentheses, ***p < 0.01, **p < 0.05, *p < 0.1.